{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T18:55:43Z","timestamp":1777661743011,"version":"3.51.4"},"reference-count":35,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T00:00:00Z","timestamp":1622160000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30ES006694"],"award-info":[{"award-number":["P30ES006694"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01ES028668"],"award-info":[{"award-number":["R01ES028668"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32ES007091"],"award-info":[{"award-number":["T32ES007091"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Pharmaceutica Sinica B"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.apsb.2021.05.030","type":"journal-article","created":{"date-parts":[[2021,6,2]],"date-time":"2021-06-02T00:29:31Z","timestamp":1622593771000},"page":"3869-3878","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Altered cisplatin pharmacokinetics during nonalcoholic steatohepatitis contributes to reduced nephrotoxicity"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4215-9434","authenticated-orcid":false,"given":"Joseph L.","family":"Jilek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kayla L.","family":"Frost","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3679-2041","authenticated-orcid":false,"given":"Kevyn A.","family":"Jacobus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenxi","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erica L.","family":"Toth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Goedken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan J.","family":"Cherrington","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.apsb.2021.05.030_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1476-5829.2007.00142.x","article-title":"Cisplatin: a review of toxicities and therapeutic applications","volume":"6","author":"Barabas","year":"2008","journal-title":"Vet Comp Oncol"},{"key":"10.1016\/j.apsb.2021.05.030_bib2","doi-asserted-by":"crossref","first-page":"14298","DOI":"10.1073\/pnas.162491399","article-title":"Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr 1 in yeast and mammals","volume":"99","author":"Ishida","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2021.05.030_bib3","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/clpt.2009.139","article-title":"Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity","volume":"86","author":"Filipski","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.apsb.2021.05.030_bib4","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1124\/mol.62.5.1154","article-title":"The copper transporter CTR1 regulates cisplatin uptake in Saccharomyces cerevisiae","volume":"62","author":"Lin","year":"2002","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.apsb.2021.05.030_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.ASN.0000042803.28024.92","article-title":"Metabolism of cisplatin to a nephrotoxin in proximal tubule cells","volume":"14","author":"Townsend","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.apsb.2021.05.030_bib6","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1042\/bj3250207","article-title":"Quantitative profiling of tissue- and gender-related expression of glutathione S-transferase isoenzymes in the mouse","volume":"325","author":"Mitchell","year":"1997","journal-title":"Biochem J"},{"key":"10.1016\/j.apsb.2021.05.030_bib7","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/0006-2952(94)90274-7","article-title":"Protection against cisplatin-induced nephrotoxicity in the rat by inducers and an inhibitor of glutathione S-transferase","volume":"48","author":"Sadzuka","year":"1994","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.apsb.2021.05.030_bib8","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.biopha.2008.08.004","article-title":"Role of glutathione S-transferase Pi in cisplatin-induced nephrotoxicity","volume":"63","author":"Townsend","year":"2009","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.apsb.2021.05.030_bib9","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1111\/j.1476-5381.2011.01394.x","article-title":"Importance of the multidrug and toxin extrusion MATE\/SLC47A family to pharmacokinetics, pharmacodynamics\/toxicodynamics and pharmacogenomics","volume":"164","author":"Yonezawa","year":"2011","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.apsb.2021.05.030_bib10","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.bcp.2010.11.016","article-title":"Organic cation transporter OCT\/SLC22A and H+\/organic cation antiporter MATE\/SLC47A are key molecules for nephrotoxicity of platinum agents","volume":"81","author":"Yonezawa","year":"2011","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.apsb.2021.05.030_bib11","first-page":"5225","article-title":"Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines","volume":"53","author":"Hamaguchi","year":"1993","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2021.05.030_bib12","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.2215\/CJN.05050610","article-title":"Relationship between kidney function and liver histology in subjects with nonalcoholic steatohepatitis","volume":"5","author":"Targher","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.apsb.2021.05.030_bib13","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/bcp.12441","article-title":"Addressing phenoconversion: the Achilles' heel of personalized medicine","volume":"79","author":"Shah","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.apsb.2021.05.030_bib14","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1124\/dmd.114.060574","article-title":"Renal xenobiotic transporter expression is altered in multiple experimental models of nonalcoholic steatohepatitis","volume":"43","author":"Canet","year":"2015","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.apsb.2021.05.030_bib15","doi-asserted-by":"crossref","first-page":"3305","DOI":"10.2337\/db14-1947","article-title":"Mechanism of altered metformin distribution in nonalcoholic steatohepatitis","volume":"64","author":"Clarke","year":"2015","journal-title":"Diabetes"},{"key":"10.1016\/j.apsb.2021.05.030_bib16","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.bcp.2016.07.001","article-title":"Effect of nonalcoholic steatohepatitis on renal filtration and secretion of adefovir","volume":"115","author":"Laho","year":"2016","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.apsb.2021.05.030_bib17","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1124\/dmd.113.055996","article-title":"Modeling human nonalcoholic steatohepatitis-associated changes in drug transporter expression using experimental rodent models","volume":"42","author":"Canet","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.apsb.2021.05.030_bib18","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1016\/j.xphs.2017.04.053","article-title":"Effect of liver disease on hepatic transporter expression and function","volume":"106","author":"Thakkar","year":"2017","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.apsb.2021.05.030_bib19","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1124\/mol.113.089805","article-title":"Renal circadian clock regulates the dosing-time dependency of cisplatin-induced nephrotoxicity in mice","volume":"85","author":"Oda","year":"2014","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.apsb.2021.05.030_bib20","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/S0022-3565(25)32105-1","article-title":"Mechanism of cis-platinum nephrotoxicity: II. Morphologic observations","volume":"213","author":"Dobyan","year":"1980","journal-title":"J Pharmacol Exp Therapeut"},{"key":"10.1016\/j.apsb.2021.05.030_bib21","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jchromb.2016.11.027","article-title":"Development and validation of a LC\u2013MS\/MS assay for quantification of cisplatin in rat plasma and urine","volume":"1046","author":"Shaik","year":"2017","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1016\/j.apsb.2021.05.030_bib22","article-title":"Validation of a routine two-sample iohexol plasma clearance assessment of GFR and an evaluation of common endogenous markers in a rat model of CKD","volume":"5","author":"Turner","year":"2017","journal-title":"Phys Rep"},{"key":"10.1016\/j.apsb.2021.05.030_bib23","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1016\/0006-2952(87)90490-4","article-title":"The comparative pharmacokinetics of carboplatin and cisplatin in mice and rats","volume":"36","author":"Siddik","year":"1987","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.apsb.2021.05.030_bib24","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1211\/0022357001777496","article-title":"Pharmacokinetics and toxicodynamics of cisplatin and its metabolites in rats: relationship between renal handling and nephrotoxicity of cisplatin","volume":"52","author":"Hanada","year":"2000","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.apsb.2021.05.030_bib25","first-page":"169","article-title":"Plasma platinum levels: relationship to cisplatin dose and nephrotoxicity","volume":"67","author":"Campbell","year":"1983","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/j.apsb.2021.05.030_bib26","doi-asserted-by":"crossref","first-page":"1462802","DOI":"10.1155\/2018\/1462802","article-title":"Cisplatin-induced rodent model of kidney injury: characteristics and challenges","volume":"2018","author":"Per\u0161e","year":"2018","journal-title":"BioMed Res Int"},{"key":"10.1016\/j.apsb.2021.05.030_bib27","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.1158\/1078-0432.CCR-07-4793","article-title":"Interaction of Cisplatin with the human organic cation transporter 2","volume":"14","author":"Filipski","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.apsb.2021.05.030_bib28","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1124\/mol.109.056416","article-title":"Mechanistic comparison of human high-affinity copper transporter 1-mediated transport between copper ion and cisplatin","volume":"76","author":"Liang","year":"2009","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.apsb.2021.05.030_bib29","doi-asserted-by":"crossref","first-page":"11199","DOI":"10.1073\/pnas.1305321110","article-title":"Oxaliplatin-induced neurotoxicity is dependent on the organic cation transporter OCT2","volume":"110","author":"Sprowl","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2021.05.030_bib30","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1124\/mol.107.040980","article-title":"Transport of cisplatin by the copper efflux transporter ATP7B","volume":"73","author":"Safaei","year":"2008","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.apsb.2021.05.030_bib31","first-page":"1312","article-title":"Copper-transporting P-type adenosine triphosphatase (ATP7B) is associated with cisplatin resistance","volume":"60","author":"Komatsu","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2021.05.030_bib32","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1124\/mol.64.2.466","article-title":"The copper export pump ATP7B modulates the cellular pharmacology of carboplatin in ovarian carcinoma cells","volume":"64","author":"Katano","year":"2003","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.apsb.2021.05.030_bib33","first-page":"473829","article-title":"Membrane transporters as mediators of Cisplatin effects and side effects","volume":"2012","author":"Ciarimboli","year":"2012","journal-title":"Sci Tech Rep (Cairo)"},{"key":"10.1016\/j.apsb.2021.05.030_bib34","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/BF00257239","article-title":"Human tissue distribution of platinum after cis-diamminedichloroplatinum","volume":"10","author":"Stewart","year":"1982","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.apsb.2021.05.030_bib35","first-page":"2125","article-title":"A case of liver toxicity following cis-dichlorodiammineplatinum(II) treatment","volume":"62","author":"Cavalli","year":"1978","journal-title":"Cancer Treat Rep"}],"container-title":["Acta Pharmaceutica Sinica B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383521002100?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383521002100?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T16:50:04Z","timestamp":1761929404000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211383521002100"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":35,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S2211383521002100"],"URL":"https:\/\/doi.org\/10.1016\/j.apsb.2021.05.030","relation":{},"ISSN":["2211-3835"],"issn-type":[{"value":"2211-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Altered cisplatin pharmacokinetics during nonalcoholic steatohepatitis contributes to reduced nephrotoxicity","name":"articletitle","label":"Article Title"},{"value":"Acta Pharmaceutica Sinica B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apsb.2021.05.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}